MA39840A - Dérivés indolés destinés à être utilisés dans le domaine de la médecine - Google Patents
Dérivés indolés destinés à être utilisés dans le domaine de la médecineInfo
- Publication number
- MA39840A MA39840A MA039840A MA39840A MA39840A MA 39840 A MA39840 A MA 39840A MA 039840 A MA039840 A MA 039840A MA 39840 A MA39840 A MA 39840A MA 39840 A MA39840 A MA 39840A
- Authority
- MA
- Morocco
- Prior art keywords
- atom
- present
- maintained
- groups
- double bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
L'invention concerne un composé inhibiteur de la tryptophane-2,3-dioxygénase (tdo) et/ou de l'indoléamine-2,3-dioxygénase (ido) destiné à être utilisé dans le domaine de la médecine, ledit composé ayant la formule suivante : dans laquelle x1, x2, x3, x4 et x5 peuvent être identiques ou différents et chacun est indépendamment choisi parmi c, n et o; chaque atome ayant une ligne en pointillé pouvant indépendamment avoir une liaison double ou une liaison simple, à condition que les valences au niveau de chaque atome soient maintenues; chaque r1, r2, r3, r4, r5 et r7 pouvant être présent ou absent et pouvant être identique ou différent et étant choisi parmi h et un groupe organique substitué ou non substitué, à condition que le nombre de tels groupes r présents soit tel que les valences de x1, x2, x3, x4 et x5 soient maintenues; un ou deux groupes r6 pouvant être présents et étant choisis parmi h et un groupe organique substitué ou non substitué, à condition que le nombre de groupes r6 présents soit tel que la valence de l'atome de carbone auquel ils sont attachés est maintenue, et à condition qu'au moins un r6 soit un groupe organique comprenant un atome ayant une double liaison à un atome d'oxygène (de préférence un groupe carbonyle ou un groupe sulphonyle) en une position α, β ou γ à l'atome de carbone auquel le r6 est attaché et dans lequel l'atome ayant une double liaison à un atome d'oxygène est également lié à un hétéro-atome.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201406154A GB201406154D0 (en) | 2014-04-04 | 2014-04-04 | Pharmaceutical compound |
GB201502156A GB201502156D0 (en) | 2015-02-10 | 2015-02-10 | Pharmaceutical compound |
PCT/EP2015/055823 WO2015150097A1 (fr) | 2014-04-04 | 2015-03-19 | Dérivés indolés destinés à être utilisés dans le domaine de la médecine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39840A true MA39840A (fr) | 2017-02-08 |
MA39840B1 MA39840B1 (fr) | 2020-10-28 |
Family
ID=52686389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39840A MA39840B1 (fr) | 2014-04-04 | 2015-03-19 | Dérivés indolés destinés à être utilisés dans le domaine de la médecine |
Country Status (26)
Country | Link |
---|---|
US (1) | US10167257B2 (fr) |
EP (1) | EP3125883B1 (fr) |
JP (2) | JP6554117B2 (fr) |
KR (1) | KR20160140892A (fr) |
CN (1) | CN106715417B (fr) |
AU (1) | AU2015239886B2 (fr) |
BR (1) | BR112016022785B8 (fr) |
CA (1) | CA2944240A1 (fr) |
CR (1) | CR20160514A (fr) |
CY (1) | CY1123548T1 (fr) |
DK (1) | DK3125883T3 (fr) |
EA (1) | EA032760B1 (fr) |
ES (1) | ES2823825T3 (fr) |
GE (1) | GEP20217247B (fr) |
HR (1) | HRP20201621T1 (fr) |
HU (1) | HUE052099T2 (fr) |
LT (1) | LT3125883T (fr) |
MA (1) | MA39840B1 (fr) |
MX (1) | MX2016012984A (fr) |
NZ (1) | NZ725860A (fr) |
PL (1) | PL3125883T3 (fr) |
PT (1) | PT3125883T (fr) |
RS (1) | RS60878B1 (fr) |
SI (1) | SI3125883T1 (fr) |
UA (1) | UA121386C2 (fr) |
WO (1) | WO2015150097A1 (fr) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE052099T2 (hu) * | 2014-04-04 | 2021-04-28 | Iomet Pharma Ltd | Indol származékok felhasználásra az orvostudományban |
GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
GB201516411D0 (en) * | 2015-09-16 | 2015-10-28 | Iomet Pharma Ltd | Pharmaceutical compound |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3377488T3 (pl) | 2015-11-19 | 2022-12-19 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
MD3394033T2 (ro) | 2015-12-22 | 2021-04-30 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
EP3394068A4 (fr) | 2015-12-24 | 2019-07-03 | Genentech, Inc. | Inhibiteurs de tdo2 |
CN107619392B (zh) * | 2016-07-15 | 2021-01-01 | 西华大学 | 1h-吲唑-4-醚类化合物及其作为ido抑制剂的用途 |
CN107033087B (zh) * | 2016-02-04 | 2020-09-04 | 西华大学 | 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途 |
WO2017156177A1 (fr) * | 2016-03-09 | 2017-09-14 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations |
CN109071457A (zh) | 2016-03-09 | 2018-12-21 | 荷兰转化研究中心有限责任公司 | 吲哚胺2,3-双加氧酶的抑制剂 |
WO2017156181A1 (fr) * | 2016-03-09 | 2017-09-14 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations |
EP3426243B1 (fr) * | 2016-03-09 | 2021-05-19 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations |
EP3426244B1 (fr) * | 2016-03-09 | 2023-06-07 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations |
JP6878460B2 (ja) * | 2016-04-15 | 2021-05-26 | 浙江中科▲創▼越▲薬▼▲業▼有限公司 | 複素環カルボン酸アミド配位子および銅触媒によるハロゲン化アリールのカップリング反応におけるその使用 |
US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2017205464A1 (fr) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Composés hétérocycliques utilisés comme immunomodulateurs |
AR108586A1 (es) * | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
MY197280A (en) | 2016-06-20 | 2023-06-09 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3484866B1 (fr) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Composés hétérocycliques utilisés comme immunomodulateurs |
CN107674029A (zh) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
WO2018044783A1 (fr) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Composés hétérocycliques utilisés comme immunomodulateurs |
US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
WO2018119236A1 (fr) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs |
KR20190111025A (ko) | 2016-12-22 | 2019-10-01 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
WO2018136437A2 (fr) | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Nouveaux composés utiles en tant qu'inhibteurs de l'indoléamine 2,3-dioxygénase et/ou du tryptophane dioxygénase |
CN108689938B (zh) * | 2017-04-10 | 2021-07-30 | 西华大学 | 多取代的吲唑类化合物及其作为ido抑制剂的用途 |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018222711A2 (fr) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunothérapeutique |
EP3669279A4 (fr) | 2017-08-14 | 2021-05-05 | Epizyme, Inc. | Procédés de traitement de cancer par inhibition de setd2 |
EP3676263B1 (fr) | 2017-09-01 | 2021-10-06 | Netherlands Translational Research Center B.V. | Composés de 3-hydroxy-imidazolidin-4-one comme inhibiteurs de l'indoléamine 2,3-dioxygénase |
CN111386114A (zh) * | 2017-11-25 | 2020-07-07 | 百济神州有限公司 | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 |
WO2019106087A1 (fr) * | 2017-11-29 | 2019-06-06 | Syddansk Universitet | Inhibiteurs d'ampk |
CN111356692B (zh) * | 2017-12-19 | 2021-09-03 | 基石药业(苏州)有限公司 | Ido抑制剂 |
CN111518076B (zh) * | 2018-01-17 | 2021-06-01 | 杭州阿诺生物医药科技有限公司 | 具有吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法 |
EP4227302A1 (fr) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Inhibiteurs de pd-1/pd-l1 |
JP2021518367A (ja) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Idoおよびtdo調節のための化合物および方法、ならびにそれらのための兆候 |
WO2019180686A1 (fr) * | 2018-03-23 | 2019-09-26 | Cmg Pharmaceutical Co., Ltd. | Inhibiteur double de ido-tdo et procédé d'utilisation associés |
PE20211911A1 (es) | 2018-03-30 | 2021-09-28 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
JOP20200288A1 (ar) | 2018-05-11 | 2020-11-11 | Incyte Corp | مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1 |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
EP3823604A4 (fr) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | Composés utiles en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase et/ou de la tryptophane dioxygénase |
CN112585119A (zh) * | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
US20210338727A1 (en) * | 2018-09-13 | 2021-11-04 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2020180882A1 (fr) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Récepteurs d'antigènes chimériques anti-cd19 et leurs utilisations en immunothérapie |
EP3936126A4 (fr) * | 2019-03-07 | 2022-12-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combinaison d'inhibiteur d'iap et d'inhibiteur de point de contrôle immunitaire |
TW202110801A (zh) * | 2019-05-16 | 2021-03-16 | 大陸商和記黃埔醫藥(上海)有限公司 | 新型醯胺類化合物及其用途 |
US20220288021A1 (en) * | 2019-07-10 | 2022-09-15 | The Trustees Of Princeton University | Method and compounds for treating or preventing autoimmune disorders or immune responses modulated by the expression of ido1 |
WO2021024020A1 (fr) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer |
AR119624A1 (es) | 2019-08-09 | 2021-12-29 | Incyte Corp | Sales de un inhibidor de pd-1 / pd-l1 |
AU2020353173A1 (en) * | 2019-09-26 | 2022-03-31 | The Global Alliance For Tb Drug Development, Inc. | Azaindole carboxamide compounds for the treatment of mycobacterial infections |
EP4037773A1 (fr) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Composés pyrido[3,2-d]pyrimidine en tant qu'immunomodulateurs |
KR20220101664A (ko) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Pd-1/pd-l1 억제제의 염 및 결정질 형태 |
IL295654A (en) * | 2020-02-19 | 2022-10-01 | Epizyme Inc | setd2 inhibitors and related methods and uses, including combination therapies |
US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2022099075A1 (fr) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Forme cristalline d'un inhibiteur pd-1/pd-l1 |
PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
TW202227424A (zh) * | 2020-11-27 | 2022-07-16 | 大陸商瑞石生物醫藥有限公司 | 芳基或雜芳基取代5員芳雜環化合物及其用途 |
WO2022135667A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Arn thérapeutique pour le traitement du cancer |
WO2022135666A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Programme de traitement faisant intervenir des protéines cytokines |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
EP4052705A1 (fr) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions pour le traitement des maladies ou des pathologies associées à l'ebv |
WO2023287704A1 (fr) * | 2021-07-12 | 2023-01-19 | Nido Biosciences, Inc. | Composés bicycliques en tant que modulateurs du récepteur des androgènes |
IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3699123A (en) | 1970-03-24 | 1972-10-17 | Sandoz Ltd | 4-(3-amino-2-hydroxy-propoxy) indole derivatives |
US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
EP1226138B1 (fr) | 1999-10-08 | 2004-12-29 | Affinium Pharmaceuticals, Inc. | Inhibiteurs de fab i |
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1345922B1 (fr) | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Composes de pyrazole utilises comme inhibiteurs de la proteine kinase |
CA2464214C (fr) * | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees |
US7838542B2 (en) * | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
WO2008036967A2 (fr) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Nouveaux composes heterocycliques utilises en tant qu'activateurs de la synthase d'acide lipoique |
EP2134683A2 (fr) | 2007-02-12 | 2009-12-23 | Intermune, Inc. | Nouveaux inhibiteurs de réplication du virus de l'hépatite c |
EP2002834A1 (fr) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryle/hétarylamides en tant que modulateurs du récepteur EP2 |
CA2699625C (fr) | 2007-10-04 | 2016-02-02 | F. Hoffmann-La Roche Ag | Derives de cyclopropyl aryl amides et leurs utilisations |
US20100035862A1 (en) | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
JP2011525915A (ja) | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
WO2011050245A1 (fr) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Hétéroaryles bicycliques formant inhibiteurs de la kinase |
WO2011056440A1 (fr) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1 |
JP2012107001A (ja) | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
US9334256B2 (en) * | 2011-06-15 | 2016-05-10 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
CN104603106B (zh) | 2012-09-07 | 2017-05-10 | 诺华股份有限公司 | 吲哚甲酰胺衍生物及其用途 |
EP2725025A1 (fr) | 2012-10-26 | 2014-04-30 | Sanofi | Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12 |
HUE052099T2 (hu) | 2014-04-04 | 2021-04-28 | Iomet Pharma Ltd | Indol származékok felhasználásra az orvostudományban |
-
2015
- 2015-03-19 HU HUE15710533A patent/HUE052099T2/hu unknown
- 2015-03-19 MX MX2016012984A patent/MX2016012984A/es unknown
- 2015-03-19 WO PCT/EP2015/055823 patent/WO2015150097A1/fr active Application Filing
- 2015-03-19 ES ES15710533T patent/ES2823825T3/es active Active
- 2015-03-19 BR BR112016022785A patent/BR112016022785B8/pt not_active IP Right Cessation
- 2015-03-19 CN CN201580030284.1A patent/CN106715417B/zh not_active Expired - Fee Related
- 2015-03-19 UA UAA201611040A patent/UA121386C2/uk unknown
- 2015-03-19 SI SI201531398T patent/SI3125883T1/sl unknown
- 2015-03-19 US US15/301,619 patent/US10167257B2/en active Active
- 2015-03-19 RS RS20201190A patent/RS60878B1/sr unknown
- 2015-03-19 LT LTEP15710533.9T patent/LT3125883T/lt unknown
- 2015-03-19 JP JP2016560772A patent/JP6554117B2/ja not_active Expired - Fee Related
- 2015-03-19 MA MA39840A patent/MA39840B1/fr unknown
- 2015-03-19 DK DK15710533.9T patent/DK3125883T3/da active
- 2015-03-19 PL PL15710533T patent/PL3125883T3/pl unknown
- 2015-03-19 GE GEAP201514317A patent/GEP20217247B/en unknown
- 2015-03-19 EA EA201692010A patent/EA032760B1/ru not_active IP Right Cessation
- 2015-03-19 AU AU2015239886A patent/AU2015239886B2/en not_active Ceased
- 2015-03-19 EP EP15710533.9A patent/EP3125883B1/fr active Active
- 2015-03-19 KR KR1020167030585A patent/KR20160140892A/ko not_active Application Discontinuation
- 2015-03-19 PT PT157105339T patent/PT3125883T/pt unknown
- 2015-03-19 CR CR20160514A patent/CR20160514A/es unknown
- 2015-03-19 CA CA2944240A patent/CA2944240A1/fr not_active Abandoned
- 2015-03-19 NZ NZ725860A patent/NZ725860A/en not_active IP Right Cessation
-
2016
- 2016-12-01 JP JP2016233718A patent/JP6134046B1/ja not_active Expired - Fee Related
-
2020
- 2020-10-08 HR HRP20201621TT patent/HRP20201621T1/hr unknown
- 2020-10-15 CY CY20201100979T patent/CY1123548T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39840A (fr) | Dérivés indolés destinés à être utilisés dans le domaine de la médecine | |
CY1124284T1 (el) | Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53 | |
EA202090676A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
MA38261A1 (fr) | Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc) | |
RU2018106483A (ru) | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr | |
JP2016513130A5 (fr) | ||
EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
AR053413A1 (es) | Antagonistas dipiperidinicos sustituidos del ccr2, composicion farmaceutica, su preparacion y uso del compuesto para preparar medicamentos | |
MA42561A (fr) | Procédés de formulation de compositions de conjugués anticorps-médicament | |
JP2016503797A5 (fr) | ||
AR078538A1 (es) | Pirroles e imidazoles sustituidos como ligandos del receptor de estrogenos | |
SI3166925T1 (en) | Isoindoline derivatives for use in treating a viral infection | |
AR070573A1 (es) | Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamento | |
MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA38275A1 (fr) | Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries | |
EA201190086A1 (ru) | Сочлененные производные имидазола в качестве антагониста trpv3 | |
EA202190398A1 (ru) | Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4 | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
WO2011158176A3 (fr) | Complexes d'or | |
EA200600998A1 (ru) | Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза | |
AR119784A1 (es) | Agentes antipalúdicos | |
EA202192760A1 (ru) | Трициклические соединения | |
RU2014139971A (ru) | Производные 1-(2-галогенобифенил-4-ил) алканкарбоновых кислот для лечения нейродегенеративных заболеваний | |
TH2001001652A (th) | อนุพันธ์ฟีนิลไพริดีนใหม่และองค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสิ่งเดียวกันนั้น |